In Reply:

This publication has 11 references indexed in Scilit:

• Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study Group
  Journal of Clinical Oncology, 2003
• Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumours
  British Journal of Surgery, 2003
• The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?
  Annals of Oncology, 2002
• Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment
  Current Opinion in Oncology, 2002
• The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials
  The Lancet, 2001
• Ultra-High-Dose Lanreotide Treatment in Patients with Metastatic Neuroendocrine Gastroenteropancreatic Tumors
  Digestion, 1999
• Combination Therapy With Octreotide and α-Interferon:
  American Journal of Gastroenterology, 1999
• High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects
  Annals of Oncology, 1997
• Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.
  Gut, 1996
• Somatostatin Analogue Phase I Trials in Neuroendocrine Neoplasms
  Acta Oncologica, 1993